Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Nebenwirkungen · Epoetin Alfa Hexal

Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 16

HOS-117300 · Präparat HOS-094569

Of a total 3 417 subjects in 25 randomised, double-blinded, placebo or standard of care controlled studies, the overall safety profile of epoetin alfa was evaluated in 2 094 anaemic subjects. Included were 228 epoetin alfa-treated CRF subjects in 4 CRF studies (2 studies in pre-dialysis [N = 131 exposed CRF subjects] and 2 in dialysis [N = 97 exposed CRF subjects]); 1 404 exposed cancer subjects in 16 studies of anaemia due to chemotherapy; 147 exposed subjects in 2 studies for autologous blood donation; 213 exposed subjects in 1 study in the perisurgical period, and 102 exposed subjects in 2 MDS studies. Adverse drug reactions reported by ≥ 1% of subjects treated with epoetin alfa in these studies are shown in the table below.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 627a8fbaf8e0545bf5bfadde1bce0f1bd2175d0289c3f4d452802ffbabf135d0 · Zeichen 954–1691 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.